Evidence map›Paper›PMID 39300461›Full record

SynthesisBMC women's health2024

Prevalence of menstrual alterations following COVID-19 vaccination: systematic review & meta-analysis.

Abeer Al Shahrani, Norah Alhumaidan, Lama Alzelfawi, Lena AlDosari, Zeena Alhindawi, Nahlah Alotaibi, Renad Aljohani

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abeer Al ShahraniDepartment of Family and Community Medicine, College of Medicine, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia. asalshahran@pnu.edu.sa.
Norah AlhumaidanCollege of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Lama AlzelfawiCollege of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Lena AlDosariCollege of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Zeena AlhindawiCollege of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Nahlah AlotaibiCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Renad AljohaniCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Funding

Princess Nourah Bint Abdulrahman University PNURSP2024R289
6 · The paper itself

Abstract

backgroundCOVID-19 vaccines can lead to diverse local and systemic side effects, but there is limited evidence concerning their association with menstrual cycle changes. This study aimed to assess the prevalence of menstrual cycle alterations after COVID-19 vaccination among adult women.

methodsWe systematically searched the PubMed, Web of Science and Science Direct databases for observational studies that included adult women and investigated the range of menstrual alterations. The quality of the studies was evaluated via the Newcastle-Ottawa scale. All the data were analyzed via Comprehensive Meta-Analysis Software Version 4.0. Forest plots were created to calculate the individual and pooled prevalence rates of different types of menstrual changes and 95% confidence intervals (CI) via fixed-effects and random-effects models, as appropriate. Heterogeneity was assessed with Q statistics and the I

resultsEleven studies, encompassing 26,283 adult women, met our eligibility criteria. Among the selected studies, five were cohort studies, five were cross-sectional studies, and one employed a case‒control design. The menstrual changes included abnormal cycle duration, dysmenorrhea, irregular cycles, and abnormal cycle flow (heavy and light flow), with pooled percentages of 27.3% (CI: 7.2-64.6%), 22% (CI: 5.2-59.4%), 16% (CI: 5.8-37.2%), 11.7% (CI: 5.8-22%), and 5.5% (CI: 2.3-12.5%), respectively.

conclusionsThis review highlights the prevalence of menstrual changes after COVID-19 vaccination and emphasizes the importance of considering menstrual health as an integral part of postvaccination monitoring and health care interventions. However, longitudinal studies are essential for establishing a definitive causal relationship between COVID-19 vaccination and menstrual alterations.

Indexed as

COVID-19COVID-19 VaccinesAdultFemaleHumansMenstruation DisturbancesPrevalenceSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19Menstrual cycleVaccine

Identifiers

PMID39300461
PMCPMC11412023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.